Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.
High-density lipoprotein (HDL) particles exhibit multiple antiatherogenic effects. They are key players in the reverse cholesterol transport which shuttles cholesterol from peripheral cells (e.g. macrophages) to the liver or other tissues. This complex process is thought to represent the basis for the antiatherogenic properties of HDL particles. The amount of cholesterol transported in HDL particles is measured as HDL cholesterol (HDLC) and is inversely correlated with the risk for coronary artery disease: an increase of 1mg/dL of HDLC levels is associated with a 2% and 3% decrease of the risk for coronary artery disease in men and women, respectively. Genetically determined conditions with high HDLC levels (e.g. familial hyperalphalipoproteinemia) often coexist with longevity, and higher HDLC levels were found among healthy elderly individuals. HDLC levels are under considerable genetic control with heritability estimates of up to 80%. The identification and characterization of genetic variants associated with HDLC concentrations can provide new insights into the background of longevity. This review provides an extended overview on the current genetic-epidemiological evidence from association studies on genes involved in HDLC metabolism. It provides a path through the jungle of association studies which are sometimes confusing due to the varying and sometimes erroneous names of genetic variants, positions and directions of associations. Furthermore, it reviews the recent findings from genome-wide association studies which have identified new genes influencing HDLC levels. The yet identified genes together explain only a small amount of less than 10% of the HDLC variance, which leaves an enormous room for further yet to be identified genetic variants. This might be accomplished by large population-based genome-wide meta-analyses and by deep-sequencing approaches on the identified genes. The resulting findings will probably result in a re-drawing and extension of the involved metabolic pathways of HDLC metabolism.
Boes
Eva
E
Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
Coassin
Stefan
S
Kollerits
Barbara
B
Heid
Iris M
IM
Kronenberg
Florian
F
D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000378:metabolism; D000369:Aged, 80 and over; D001053:Apolipoproteins / Q000235:genetics; D001692:Biological Transport / Q000235:genetics; D002265:Carboxylic Ester Hydrolases / Q000235:genetics / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins / Q000235:genetics*; D008076:Cholesterol, HDL / Q000235:genetics* / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000235:genetics / Q000378:metabolism; D016206:Databases, Bibliographic; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D054439:Ghrelin / Q000235:genetics; D006801:Humans; D052456:Hypoalphalipoproteinemias / Q000235:genetics / Q000378:metabolism; D008136:Longevity / Q000235:genetics; D008297:Male; D057182:Mendelian Randomization Analysis; D015201:Meta-Analysis as Topic; D017720:Molecular Epidemiology; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000235:genetics / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D051122:Scavenger Receptors, Class B / Q000235:genetics / Q000378:metabolism
D018528:ATP-Binding Cassette Transporters; D001053:Apolipoproteins; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D054439:Ghrelin; D051122:Scavenger Receptors, Class B; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D002265:Carboxylic Ester Hydrolases